See more : Giantec Semiconductor Corporation (688123.SS) Income Statement Analysis – Financial Results
Complete financial analysis of Indegene Limited (INDGN.NS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Indegene Limited, a leading company in the Medical-Healthcare Information Services industry within the Healthcare sector.
- Austar Lifesciences Limited (6118.HK) Income Statement Analysis – Financial Results
- Golden Star Acquisition Corporation (GODNU) Income Statement Analysis – Financial Results
- Telefónica, S.A. (TEF) Income Statement Analysis – Financial Results
- Sweeten Real Estate Development Co.,Ltd. (5525.TW) Income Statement Analysis – Financial Results
- NatWest Group plc (RBSPF) Income Statement Analysis – Financial Results
Indegene Limited (INDGN.NS)
Industry: Medical-Healthcare Information Services
Sector: Healthcare
Website: https://www.indegene.com
About Indegene Limited
Indegene Limited operates as a life sciences commercialization company in India and internationally. It helps biopharmaceutical, emerging biotech, and medical device companies develop products, get to the market, and grow impact through the life cycle. The company offers enterprise commercial solutions, enterprise medical solutions, enterprise clinical solutions, omnichannel activation solutions, and NEXT technology platforms. The company was incorporated in 1998 and is based in Bengaluru, India.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 25.90B | 23.06B | 16.65B | 9.66B | 6.44B |
| Cost of Revenue | 588.00M | 412.42M | 324.59M | 156.46M | 109.71M |
| Gross Profit | 25.31B | 22.65B | 16.32B | 9.51B | 6.33B |
| Gross Profit Ratio | 97.73% | 98.21% | 98.05% | 98.38% | 98.30% |
| Research & Development | 0.00 | 0.00 | 0.00 | 88.30M | 122.96M |
| General & Administrative | 0.00 | 858.09M | 544.61M | 372.45M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 16.56B | 858.09M | 544.61M | 372.45M | 3.74B |
| Other Expenses | 0.00 | 9.80M | 10.97M | 9.72M | 0.00 |
| Operating Expenses | 16.56B | 19.70B | 14.11B | 7.47B | 5.51B |
| Cost & Expenses | 17.15B | 19.70B | 14.11B | 7.47B | 5.62B |
| Interest Income | 494.00M | 103.05M | 8.03M | 8.85M | 58.84M |
| Interest Expense | 0.00 | 232.91M | 46.70M | 391.28M | 0.00 |
| Depreciation & Amortization | 506.00M | 598.10M | 334.51M | 346.02M | 89.75M |
| EBITDA | 4.85B | 4.54B | 2.66B | 2.60B | 1.34B |
| EBITDA Ratio | 18.74% | 19.05% | 18.44% | 26.94% | 20.81% |
| Operating Income | 8.75B | 3.79B | 2.74B | 2.26B | 1.25B |
| Operating Income Ratio | 33.78% | 16.45% | 16.43% | 23.36% | 19.42% |
| Total Other Income/Expenses | -4.16B | -4.33B | -290.68M | -1.84B | -493.17M |
| Income Before Tax | 4.59B | 3.63B | 2.26B | 2.31B | 758.00M |
| Income Before Tax Ratio | 17.71% | 15.74% | 13.61% | 23.95% | 11.78% |
| Income Tax Expense | 1.22B | 969.48M | 636.78M | 457.80M | 261.16M |
| Net Income | 3.37B | 2.66B | 1.65B | 1.49B | 558.08M |
| Net Income Ratio | 13.00% | 11.54% | 9.90% | 15.46% | 8.67% |
| EPS | 15.07 | 11.12 | 6.89 | 6.24 | 2.83 |
| EPS Diluted | 15.07 | 11.12 | 6.89 | 6.24 | 2.83 |
| Weighted Avg Shares Out | 223.42M | 239.27M | 239.27M | 239.27M | 197.46M |
| Weighted Avg Shares Out (Dil) | 223.45M | 239.27M | 239.27M | 239.27M | 197.40M |
Source: https://incomestatements.info
Category: Stock Reports